Empower Testosterone Cypionate Injection 50 mg/mL – 5 mL Vial

Description

(Testosterone Cypionate, USP – Sterile Intramuscular Injection)

Low-Concentration, Precision-Dosed Testosterone Therapy for Personalized Hormone Optimization

Empower Testosterone Cypionate 50 mg/mL is a sterile, preservative-free, bioidentical testosterone formulation intended for intramuscular administration in men with clinically diagnosed testosterone deficiency. Compounded by Empower Pharmacy under strict USP <797> sterile compounding standards, this formulation provides precise hormone dosing for tailored testosterone replacement therapy (TRT) protocols.

Packaged in a 5 mL multidose vial, this lower-concentration formulation is ideal for patients initiating therapy, those requiring microdosing protocols, or individuals sensitive to fluctuations in hormone levels. The 50 mg/mL strength allows for high dosing accuracy and titration flexibility, especially in hormone optimization clinics, integrative practices, or telemedicine-based TRT programs.

Key Features and Benefits

  • Low-dose testosterone (50 mg/mL) for controlled and gradual titration

  • Packaged in a 5 mL sterile vial for multiple administrations

  • Ideal for microdosing, beginners in TRT, or estrogen-sensitive patients

  • Bioidentical testosterone cypionate suspended in a clean, oil-based carrier

  • Sterile, preservative-free formulation compounded by Empower Pharmacy

  • Allows for more stable serum testosterone levels with frequent low-dose injections

  • Minimizes peak-trough variability and reduces side effects associated with supraphysiologic dosing

Clinical Indications

Testosterone Cypionate Injection 50 mg/mL is indicated for:

  • Primary hypogonadism (e.g., testicular failure, Klinefelter syndrome)

  • Secondary hypogonadism (e.g., pituitary dysfunction, trauma, or tumors)

  • Age-related testosterone decline in symptomatic men

  • Transgender hormone therapy (FTM) protocols requiring conservative dosing

  • Testosterone optimization programs under physician supervision

This formulation is for men with documented low testosterone levels confirmed through lab testing and symptoms consistent with hypogonadism. It is not indicated for athletic enhancement or non-medical use.

Mechanism of Action

Testosterone cypionate is an esterified form of testosterone that is slowly absorbed from the intramuscular injection site and hydrolyzed into free, bioactive testosterone. Once in circulation, it binds to androgen receptors in various tissues, regulating:

  • Muscle growth and protein synthesis

  • Fat distribution and metabolism

  • Libido and sexual function

  • Mood, cognition, and energy levels

  • Bone density and cardiovascular health

The 50 mg/mL concentration allows for precise modulation of testosterone levels and better management of symptom variability, particularly in sensitive or new TRT patients.

Dosing and Administration

  • Route: Intramuscular (IM), typically in the gluteal or thigh muscle

  • Typical starting dose: 50 mg to 100 mg per week, divided across 1–3 injections

  • Microdosing protocols: 10–20 mg every other day or multiple small doses weekly

  • Administer with sterile injection technique, rotate injection sites

  • Injection volume is small and comfortable, thanks to the low-concentration formulation

  • The 5 mL vial contains 250 mg of testosterone total (50 mg/mL × 5 mL)

Dosing should always be determined by a healthcare provider based on lab values, clinical symptoms, age, weight, and comorbidities.

Expected Clinical Benefits

When administered appropriately and monitored routinely, patients can expect:

  • Increased energy, strength, and physical performance

  • Improved mood, motivation, and sleep quality

  • Enhanced libido, erectile function, and sexual satisfaction

  • Reduction in brain fog, irritability, and fatigue

  • Preservation or increase in lean muscle mass

  • Better recovery and metabolic function

Most patients begin to feel improvement within 4–6 weeks, with full therapeutic benefit apparent by 12 weeks.

Monitoring and Follow-up

Ongoing laboratory testing is required to ensure safety and effectiveness:

  • Total and Free Testosterone

  • Estradiol (E2) – to monitor aromatization

  • Hematocrit and Hemoglobin – to detect erythrocytosis

  • Liver Function Tests (LFTs) and lipid panel

  • Prostate-Specific Antigen (PSA) for men over 40

Safety, Side Effects & Contraindications

Common side effects (typically dose- or estrogen-related):

  • Acne, oily skin

  • Water retention

  • Mood swings

  • Increased hematocrit

  • Elevated estradiol (E2)

Serious risks (require close monitoring):

  • Polycythemia

  • Gynecomastia

  • Prostate enlargement (in older men)

Contraindications:

  • Known or suspected prostate or breast cancer in men

  • Severe untreated sleep apnea

  • Polycythemia (hematocrit >54%)

  • Allergy to testosterone or formulation components

Storage and Handling

  • Store at controlled room temperature (15°C to 25°C / 59°F to 77°F)

  • Protect from light and moisture

  • Do not freeze

  • Use a sterile syringe for each administration

  • Keep out of reach of children

Ideal Use Cases

This 50 mg/mL testosterone formulation is best suited for:

  • New TRT patients who require gradual titration

  • Microdosing protocols to reduce peak-trough variability

  • Men with estrogen sensitivity or who are prone to side effects at higher concentrations

  • Providers aiming for fine control over serum levels using smaller injection volumes more frequently

  • FTM patients seeking lower-dose transition therapy

Empower Testosterone Cypionate 50 mg/mL (5 mL) is a refined, precise, and clinically trusted option for low-dose, personalized hormone replacement therapy. Designed for flexibility, stability, and comfort, this formulation empowers both providers and patients to manage testosterone deficiency safely and effectively.

 

Reviews

There are no reviews yet.

Be the first to review “Empower Testosterone Cypionate Injection 50 mg/mL – 5 mL Vial”

Your email address will not be published. Required fields are marked *